Related Experiment Video
Updated: Apr 21, 2026
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Primary Brain Tumor Radiotherapy with Concurrent and Adjuvant Temozolomide: Its Outcomes in Terms of Survival and
Manraj S Kang1, Simrandeep Singh2, Taranjeet Kaur3
1Department of Radiation Oncology, Government Medical College, Amritsar, Punjab, India.
Background:
To assess the outcome of primary brain tumor radiotherapy with concurrent and adjuvant temozolomide.
Material And Methods:
A total of 42 patients who were histologically proven primary malignant brain tumor with nonmetastatic, ECOG (Eastern Cooperative Oncology Group) performance status 0, 1, and 2 were enrolled in this study.
Results:
All patients underwent craniotomy with gross total excision (GTE) 66.7% and partial excision 33.3%. Post craniotomy, patients were diagnosed as grade II 28.6%, grade III 23.8%, grade IV 42.9%, and glio-sarcoma 4.8%. Post radiotherapy with concurrent and adjuvant temozolomide, two years of overall survival were 83.3%, 60%, and 25% in grade II, grade III, and high-grade glioma, respectively.
Conclusion:
This study concluded that radiotherapy is an integral part of treatment in primary malignant brain tumor. Temozolomide (TMZ) in concurrent and adjuvant setting had additional survival benefit.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers